Pulmonary Fibrosis

  • Medical Author:
    George Schiffman, MD, FCCP

    Dr. Schiffman received his B.S. degree with High Honors in biology from Hobart College in 1976. He then moved to Chicago where he studied biochemistry at the University of Illinois, Chicago Circle. He attended Rush Medical College where he received his M.D. degree in 1982 and was elected to the Alpha Omega Alpha Medical Honor Society. He completed his Internal Medicine internship and residency at the University of California, Irvine.

  • Medical Editor: Melissa Conrad Stöppler, MD
    Melissa Conrad Stöppler, MD

    Melissa Conrad Stöppler, MD

    Melissa Conrad Stöppler, MD, is a U.S. board-certified Anatomic Pathologist with subspecialty training in the fields of Experimental and Molecular Pathology. Dr. Stöppler's educational background includes a BA with Highest Distinction from the University of Virginia and an MD from the University of North Carolina. She completed residency training in Anatomic Pathology at Georgetown University followed by subspecialty fellowship training in molecular diagnostics and experimental pathology.

Understanding COPD

What is the prognosis for pulmonary fibrosis?

The prognosis of this disease is poor. The survival of patients with this disease is less than 5 years. It is probably best to become involved with an academic center in the area where research on interstitial lung diseases is studied in order to receive the latest treatments. These centers often are linked with a lung transplant program. Clinical trials are the best way of treating this disease at this time.

Where can I get information to improve the quality of life for those with pulmonary fibrosis?

For information quality of life and living with pulmonary fibrosis please visit Pulmonaryfibrosis.org.


Nathan, S. MD. et al. "Long-term Course and Prognosis of Idiopathic Pulmonary Fibrosis in the New Millennium." Chest. 2011;140(1):221-229. Pulmonaryfibrosis.org.

Raghu. et al. "An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline" Am J resp crit care medicine abstract 2015; 192; e3-19.

Richeldi. et al. "Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis." N Engl J Med 2014; 370:2071-2082.

Talmadge. et al. "A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis." N Engl J Med 2014; 370:2083-2092.

Medically Reviewed by a Doctor on 8/11/2015

Subscribe to MedicineNet's Allergy and Asthma Newsletter

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

  • Pulmonary Fibrosis - Treatments

    What treatments have been helpful with your pulmonary fibrosis?

    Post View 18 Comments
  • Pulmonary Fibrosis - Experience

    If known, what was the cause of your pulmonary fibrosis? Please share your experience.

    Post View 23 Comments
  • Pulmonary Fibrosis - Symptoms

    What were your symptoms associated with pulmonary fibrosis?

    Post View 8 Comments
  • Pulmonary Fibrosis - Cause

    If known, what caused your pulmonary fibrosis?

    Post View 3 Comments

Health Solutions From Our Sponsors